What You Should Know
– Prescryptive and Ilant Health have partnered to offer employers a direct-to-market channel for GLP-1 therapies, combining transparent net pricing with rigorous clinical oversight.
– The collaboration utilizes Prescryptive’s claims platform and Ilant’s Center of Excellence (COE) model to deliver an average 15% weight loss for participants while ensuring that 90% of members remain on therapy at the six-month mark.
The Operating Model: Aligning Clinical Guardrails with Predictable Economics
The “GLP-1 gold rush” has left many employers in a financial tailspin, with traditional PBM (Pharmacy Benefit Manager) models often criticized for lack of transparency and clinical follow-up. Prescryptive and Ilant are disrupting this by building a “closed-loop, incentive-aligned” ecosystem.
- Prescryptive’s Direct-to-Market Platform: Enables employers to access net pricing directly from manufacturers, bypassing traditional middlemen. It enforces eligibility rules and program clinical oversight at the point of sale.
- Ilant’s Center of Excellence (COE): Provides structured clinical pathways, including high-value prescribing, lifestyle support, and nationwide clinical coverage.
- Direct Access Marketplace: A national pharmacy network ensures coordinated fulfillment and consistent program execution across all 50 states.
Reported Clinical Outcomes for Ilant Members:
- Therapy Retention: Over 90% of enrolled members remain on therapy at 6 months, compared to the industry average which is significantly lower.
- Weight Loss: An average of 15% weight loss across multiple treatment modalities.
- Preventative Care Integration: 25%+ of members had not seen a regular physician in the last year before joining, indicating that the COE is closing a critical primary care gap.
Configurable Benefit Design
Many direct-access models are rigid, but Prescryptive’s platform allows for configurable employer benefit design. This means an employer can tailor the program to their specific workforce demographics while still benefiting from the “predictable economics” of the direct-access channel.
According to Chris Blackley, CEO of Prescryptive, this is the missing piece of the puzzle: “Employer-direct GLP-1 access requires more than pricing innovation. It requires an operating model that aligns clinical oversight, predictable economics, and accountable access”.
